CTY:NASDAQ, City Therapeutics Inc.

Why CTY stock rose on November 19

City Therapeutics Inc. rose 10.3% on Thursday, November 19, 2026, on 245,887 shares. No headline about CTY came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.

CTY stock overview

City Therapeutics Inc. (CTY:NASDAQ) closed at $20.04 on November 20, 2026, up 9.21% on the day. The stock trades 16.1% below its 52-week high of $23.88 and 26.8% above its 52-week low of $15.81. Over the past year, it lost 18.1%. City Therapeutics Inc. is part of the Health Care sector.

Key figures

Price
$20.04
Day change
+9.21%
Volume
108,279
Average volume
332,020
Market cap
1B+
52-week range
$15.81 – $23.88
50-day average
$19.45
200-day average
$19.45

Price action over the past year

In 24 trading sessions since October 19, 2026, CTY closed higher on 13 days (54%). Its best day was November 12, 2026 (+11.58%) and its worst was November 4, 2026 (-14.04%). The stock moved 10% or more in a single session 4 times.

Recent signals

CTY news

About City Therapeutics Inc.

City Therapeutics is a clinical-stage biotechnology company engineering the next generation of RNA interference (RNAi) therapeutics, with the aim of delivering meaningful and durable benefits for patients in need. City's lead development programs are CITY-FXI for thromboembolic diseases, CITY-RBP4 for Stargardt disease and other retinal diseases, and CITY-TFR2 for anemia associated with chronic diseases. The City Platform is the engine behind every therapeutic the company develops and integrates deep expertise in trigger engineering, including proprietary cityRNA triggers designed to address limitations of conventional RNAi approaches, tissue-selective delivery, and genetics-driven target selection.

Similar stocks

Find more stocks like CTY with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.